Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 8, 2016
Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatmentD Ovejero, Y H Lim, A M Boyce, et al.The British Journal of Dermatology|September 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension studyM J Cork, D Thaçi, L F Eichenfield, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 18, 2023
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent eventsR Bissonnette, L F Eichenfield, E Simpson, et al.The British Journal of Dermatology|March 20, 2014
Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomaliesA Munden, R Butschek, W L Tom, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2019
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinionJ P Thyssen, M S de Bruin-Weller, A S Paller, et al.The British Journal of Dermatology|February 6, 2019
TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registriesF M Vermeulen, L A A Gerbens, A L Bosma, et al.The British Journal of Dermatology|May 16, 2018
TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registriesL A A Gerbens, C J Apfelbacher, A D Irvine, et al.The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.The British Journal of Dermatology|August 25, 2019
TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczemaA L Bosma, P I Spuls, I Garcia-Doval, et al.Pageof 7